{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:03:53Z","timestamp":1779163433402,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","award":["F. Hoffmann-La Roche"],"award-info":[{"award-number":["F. Hoffmann-La Roche"]}],"id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00417-025-07000-7","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:56:53Z","timestamp":1761710213000},"page":"141-148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["POYANG: A phase III randomized clinical trial of faricimab for choroidal neovascularization secondary to pathologic myopia: study design and rationale"],"prefix":"10.1007","volume":"264","author":[{"given":"Timothy Y. Y.","family":"Lai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Arias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chui Ming Gemmy","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Couturier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia E.","family":"O\u2019Leary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neala","family":"Rafijah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Hee","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shriji","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"On behalf of the POYANG Study investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"issue":"5","key":"7000_CR1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","volume":"123","author":"BA Holden","year":"2016","unstructured":"Holden BA, Fricke TR, Wilson DA et al (2016) Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 123(5):1036\u20131042","journal-title":"Ophthalmology"},{"issue":"1","key":"7000_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.47102\/annals-acadmedsg.V33N1p27","volume":"33","author":"LL Lin","year":"2004","unstructured":"Lin LL, Shih YF, Hsiao CK, Chen CJ (2004) Prevalence of myopia in Taiwanese schoolchildren: 1983 to 2000. Ann Acad Med Singapore 33(1):27\u201333","journal-title":"Ann Acad Med Singapore"},{"issue":"3","key":"7000_CR3","doi-asserted-by":"publisher","first-page":"M20","DOI":"10.1167\/iovs.18-25957","volume":"60","author":"DI Flitcroft","year":"2019","unstructured":"Flitcroft DI, He M, Jonas JB (2019) IMI - Defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. Invest Ophthalmol Vis Sci 60(3):M20\u2013M30","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"7000_CR4","doi-asserted-by":"crossref","unstructured":"Rashid A, Grossniklaus HE (2014) Update on the pathology of pathological myopia. In: Spaide RF, Ohno-Matsui K, Yannuzzi LA (eds) Pathologic myopia. Springer New York, New York, NY, pp 83\u201395","DOI":"10.1007\/978-1-4614-8338-0_7"},{"issue":"13","key":"7000_CR5","first-page":"3287","volume":"40","author":"Y Seko","year":"1999","unstructured":"Seko Y, Seko Y, Fujikura H, Pang J, Tokoro T, Shimokawa H (1999) Induction of vascular endothelial growth factor after application of mechanical stress to retinal pigment epithelium of the rat in vitro. Invest Ophthalmol Vis Sci 40(13):3287\u20133291 PMID: 10586955","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"7000_CR6","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.ophtha.2017.04.028","volume":"124","author":"CMG Cheung","year":"2017","unstructured":"Cheung CMG, Arnold JJ, Holz FG et al (2017) Myopic choroidal neovascularization: Review, Guidance, and consensus statement on management. Ophthalmology 124(11):1690\u20131711","journal-title":"Ophthalmology"},{"issue":"8","key":"7000_CR7","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/S0161-6420(96)30515-0","volume":"103","author":"SY Cohen","year":"1996","unstructured":"Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ (1996) Etiology of choroidal neovascularization in young patients. Ophthalmology 103(8):1241\u20131244","journal-title":"Ophthalmology"},{"key":"7000_CR8","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.preteyeres.2017.10.005","volume":"63","author":"K Ohno-Matsui","year":"2018","unstructured":"Ohno-Matsui K, Ikuno Y, Lai TYY, Gemmy Cheung CM (2018) Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. Prog Retin Eye Res 63:92\u2013106","journal-title":"Prog Retin Eye Res"},{"issue":"8","key":"7000_CR9","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1097\/IAE.0b013e318285cc24","volume":"33","author":"HM Kang","year":"2013","unstructured":"Kang HM, Koh HJ (2013) Ocular risk factors for recurrence of myopic choroidal neovascularization: long-term follow-up study. Retina 33(8):1613\u20131622","journal-title":"Retina"},{"issue":"7","key":"7000_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0271342","volume":"17","author":"M Jain","year":"2022","unstructured":"Jain M, Narayanan R, Jana P (2022) Incidence, predictors and re-treatment outcomes of recurrent myopic choroidal neo-vascularization. PLoS ONE 17(7):e0271342","journal-title":"PLoS ONE"},{"issue":"11","key":"7000_CR11","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"JT Regula","year":"2016","unstructured":"Regula JT, von Lundh P, Foxton R et al (2016) Targeting key angiogenic pathways with a bispecific crossmab optimized for neovascular eye diseases. EMBO Mol Med 8(11):1265\u20131288.","journal-title":"EMBO Mol Med"},{"key":"7000_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2023.1192464","volume":"17","author":"J Canonica","year":"2023","unstructured":"Canonica J, Foxton R, Garrido MG (2023) Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia\/reperfusion. Front Cell Neurosci 17:1192464","journal-title":"Front Cell Neurosci"},{"issue":"10326","key":"7000_CR13","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399(10326):729\u2013740","journal-title":"Lancet"},{"issue":"10326","key":"7000_CR14","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP (2022) Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet 399(10326):741\u2013755","journal-title":"Lancet"},{"issue":"8","key":"7000_CR15","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","volume":"131","author":"R Tadayoni","year":"2024","unstructured":"Tadayoni R, Paris LP, Danzig CJ et al (2024) Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-Week results from the BALATON and COMINO trials. Ophthalmology 131(8):950\u2013960","journal-title":"Ophthalmology"},{"key":"7000_CR16","unstructured":"New data for Roche\u2019s Vabysmo reinforce its efficacy, safety and durability in neovascular or wet age-related macular degeneration (nAMD). 2025 [Press Release] https:\/\/www.roche.com\/investors\/updates\/inv-update-2025-09-05"},{"issue":"3","key":"7000_CR17","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","volume":"121","author":"S Wolf","year":"2014","unstructured":"Wolf S, Balciuniene VJ, Laganovska G et al (2014) RADIANCE: a randomized controlled study of Ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 121(3):682\u2013692e682","journal-title":"Ophthalmology"},{"issue":"10","key":"7000_CR18","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1097\/IAE.0000000000002292","volume":"39","author":"Y Chen","year":"2019","unstructured":"Chen Y, Sharma T, Li X et al (2019) RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN ASIAN PATIENTS WITH MYOPIC CHOROIDAL NEOVASCULARIZATION: BRILLIANCE, a 12-Month, Randomized, Double-Masked study. Retina 39(10):1985\u20131994","journal-title":"Retina"},{"issue":"6","key":"7000_CR19","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","volume":"122","author":"Y Ikuno","year":"2015","unstructured":"Ikuno Y, Ohno-Matsui K, Wong TY et al (2015) Intravitreal Aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study. Ophthalmology 122(6):1220\u20131227","journal-title":"Ophthalmology"},{"key":"7000_CR20","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2147\/OPTH.S49437","volume":"9","author":"L El Matri","year":"2015","unstructured":"El Matri L, Chebil A, Kort F (2015) Current and emerging treatment options for myopic choroidal neovascularization. Clin Ophthalmol 9:733\u2013744","journal-title":"Clin Ophthalmol"},{"key":"7000_CR21","doi-asserted-by":"publisher","unstructured":"Swaminathan S, Mahmoudzadeh R, Wakabayashi T et al (2024) Outcomes of pro re Nata versus Treat-and-Extend Anti-VEGF injections for myopic macular neovascularization in multiethnic patients in the united States. Retina 2024 Dec 1;44(12):2057-2065. https:\/\/doi.org\/10.1097\/IAE.0000000000004256 .","DOI":"10.1097\/IAE.0000000000004256"},{"issue":"1","key":"7000_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227557","volume":"15","author":"RD Hamilton","year":"2020","unstructured":"Hamilton RD, Clemens A, Minnella AM, LUMINOUS study group et al (2020) Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: results from the LUMINOUS study. PLoS ONE 15(1):e0227557. https:\/\/doi.org\/10.1371\/journal.pone.0227557","journal-title":"PLoS ONE"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-07000-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-07000-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-07000-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T04:44:10Z","timestamp":1771044250000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-07000-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7000"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-07000-7","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study protocol was approved by the responsible IRB\/EC at each participating center before the studies began (see full list in Appendix).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Funding:","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Financial support was provided by F. HoffmannLa Roche Ltd. (Basel,Switzerland). The sponsor participated in the design of the study; collection, management,analysis, and interpretation of the data; preparation, review, and approval of the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial Support"}},{"value":"For up-to-date details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here:\n                      \n                      . Anonymized records for individual patients across more than one data source external to Roche cannot, and should not, be linked due to a potential increase in risk of patient re-identification. Requests for the data underlying this publication requires a detailed, hypothesis-driven statistical analysis plan that is collaboratively developed by the requestor and company subject matter experts. Direct such requests to Roche for consideration.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Roche Data Sharing Statement"}},{"value":"Information in this manuscript, in part, has been presented at the following congresses: -55\n                      th\n                      Annual Scientific Congress of The Royal Australian and New Zealand College of Ophthalmologists, Adelaide, 1-4\n                      th\n                      November 2024-12\n                      th\n                      FLORETINA Congress, Florence, Italy, 5-8 December 2024- 40\n                      th\n                      Asia-Pacific Academy of Ophthalmology Congress, New Delhi, India, 3\n                      rd\n                      -6\n                      th\n                      April 2025","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Meeting Presentation"}},{"value":"The author(s) have made the following disclosure(s): T.L: Funding: Allergan, Bayer, Novartis, Roche; Consultancy: Alcon, Allergan, Astellas, Bayer, Boehringer Ingelheim, Novartis, Ocular Therapeutix, Oculis, Roche L.A: Consultant \u2014 Allergan, Bayer, Novartis, Roche, and Topcon G.C.: Consultant \u2014 Allergan, Bayer, Boehringer Ingelheim, Novartis, Roche, Samsung, Topcon A.C.: Consultant \u2014 Abbvie, Alcon, Bayer, Novartis, Horus, Roche, Zeiss W.L.: Employee \u2014 F. Hoffmann-La Roche Ltd. O.O.: Employee \u2014 F. Hoffmann-La Roche Ltd. N.R: Employee \u2014 Genentech, Inc. N.S: None Y.Y: Consultant \u2014\u00a0Bayer, Roche, Samsung Bioepis; Funding \u2013\u00a0Bayer, Celltrion, Kyowa Kirin, Novartis, Opthea, Samsung Bioepis, Roche; Speaker \u2013\u00a0Bayer, Roche. S.P.: Employee \u2014 Genentech, Inc.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}